Patients in the SNCP group also received more treatment for diabetes (oral antidiabetic and insulin) and for cardiovascular disease (ARB/calcium antagonist/statins/antiplatelets), with poorer HbA1c (7.25% vs. 7.12%; p<0.001), and better LDL cholesterol (115 mg/dl vs. 119 mg/dl; p<0.001), than patients of the UNC group. The gene discussed is INS; the disease is diabetes mellitus.